l≡eahp



# OPTIMISATION OF THE BLOOD DERIVED MEDICINES CIRCUIT BY COLLECTING AND ANALYZING NON-COMPLIANCES


<u>H. Mazaré</u><sup>1</sup>, M. Megne Wabo<sup>1</sup>, A. Berroneau<sup>1</sup>, V. Servant<sup>1</sup>, M. Puntous<sup>2</sup>, S. Djabarouti<sup>1</sup>, F. Xuereb<sup>1</sup>, D. Breilh<sup>1</sup>. <sup>1</sup>Bordeaux University hospital, Pharmacy, Pessac, France ; <sup>2</sup>Bordeaux University hospital, Hemovigilance, Pessac, France

#### Background

Blood-derived medicines (BDM) have a particular status because of their origin and their theoretical infectious risk strict regulation

**Specific circuit** in our hospital but **numerous dysfunctions** identified daily by the BDM team in the pharmacy






### Purpose

To identify recurrent non-compliances in the BDM circuit in order to set up specific and efficient actions to improve this circuit.

# **Material and methods**

Pharmacist and pharmacy technician collected non-compliances at each stage of the BDM circuit : from prescription to administration's traceability over an 8-months period (March 2015 to November 2015)

### Results



# Conclusion

- Identification of critical points in the BDM circuit is most of non-compliances affected administration's traceability of the BDM
- Improvements actions :
  - development of training actions about circuit and management of BDM
  - information documents have been created to secure each step of the circuit
  - evaluation of professionnal practices in progress to evaluate these improvements actions